The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)

The Baruch Padeh Medical Center, Poriya60 enrolled

Overview

To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pregnancy Result Rape

Interventions

LeuverisDRUG

All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.

Eligibility

Sex: FEMALEMin age: 25 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * female candidate to IVF * between 30-45 years old Exclusion Criteria: * not included for fertilization

Locations (1)

Poriya hospital

Tiberias, Israel

Outcomes

Primary Outcomes

Pregnancy rate

Time frame: Starting February 2010

Secondary Outcomes

Fertilization rate

Time frame: Starting February 2010 till April 2013

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.